Takeda Pharmaceutical (TAK) FCF Margin (2018 - 2026)

Takeda Pharmaceutical's FCF Margin history runs 9 years deep, the most recent figure standing at 11.04% for Q1 2026.

• In Q1 2026, FCF Margin fell 1138.0% year-over-year to 11.04%; the TTM figure through Mar 2026 stood at 17.6% (down 29.0% YoY), while the FY2026 annual figure was 27.02%, down 44.0% from the prior year.
• FCF Margin was 11.04% for Q1 2026 at Takeda Pharmaceutical, down from 37.91% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 40.78% in Q4 2024 to a low of 9.37% in Q3 2024.
• Historically, FCF Margin has averaged 21.09% across 5 years, with a median of 18.85% in 2024.
• The sharpest annual moves came in 2023 and 2024: FCF Margin sank 1913 bps in 2023, then soared 2236 bps in 2024.
• A 5-year view of FCF Margin shows it stood at 37.54% in 2022, then slumped by 51 bps to 18.42% in 2023, then jumped by 121 bps to 40.78% in 2024, then dropped by 7 bps to 37.91% in 2025, then slumped by 71 bps to 11.04% in 2026.
• The last three FCF Margin figures came in at 11.04% (Q1 2026), 37.91% (Q4 2025), and 11.86% (Q3 2025), per Business Quant data.